New Inhibitor Targets Mitochondrial Glutamine Transporter SLC1A5 Variant to Disrupt Cancer Cell Metabolism

Researchers have identified a new therapeutic target aimed at addressing the metabolic vulnerabilities of cancer cells. The study introduces a first-of-its-kind inhibitor that specifically disrupts the function of the mitochondrial glutamine transporter SLC1A5 variant (SLC1A5_var). This transporter plays a critical role in supporting cancer cell metabolism, making it a potential avenue for treatment strategies.

The research team, led by Sung, Yu, Lee, and colleagues, focused on targeting SLC1A5_var due to its involvement in transporting glutamine into mitochondria—a process essential for energy production and biosynthesis in rapidly growing cancer cells. By inhibiting this transporter, the newly developed compound aims to interfere with cancer cell growth and survival. The findings highlight the importance of targeting metabolic pathways unique to cancer cells as part of therapeutic development efforts.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: November 3, 2025

Author

GOAI